The stock of Puretech Health PLC (LON:PRTC) is a huge mover today! The stock increased 3.08% or GBX 4 on November 4, hitting GBX 134. About 12,695 shares traded hands. Puretech Health PLC (LON:PRTC) has declined 3.42% since April 6, 2016 and is downtrending. It has underperformed by 4.51% the S&P500.
The move comes after 6 months positive chart setup for the GBX 316.76M company. It was reported on Nov, 4 by Barchart.com. We have GBX 297.48 PT which if reached, will make LON:PRTC worth GBX 386.45M more.
Puretech Health PLC (LON:PRTC) Ratings Coverage
Out of 4 analysts covering Puretech Health Plc (LON:PRTC), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Puretech Health Plc has been the topic of 40 analyst reports since July 30, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Thursday, October 29 by Liberum Capital. The stock has “Buy” rating given by Jefferies on Friday, December 18. The stock has “Buy” rating given by Liberum Capital on Wednesday, August 17. Jefferies maintained Puretech Health PLC (LON:PRTC) rating on Monday, November 9. Jefferies has “Buy” rating and GBX 235 price target. The firm has “Buy” rating by Jefferies given on Thursday, October 29. The firm earned “Buy” rating on Thursday, May 19 by Numis Securities. Peel Hunt maintained Puretech Health PLC (LON:PRTC) rating on Thursday, May 5. Peel Hunt has “Buy” rating and GBX 220 price target. Peel Hunt maintained Puretech Health PLC (LON:PRTC) rating on Thursday, June 2. Peel Hunt has “Buy” rating and GBX 220 price target. The rating was maintained by Peel Hunt on Monday, November 30 with “Buy”. The firm has “Buy” rating given on Thursday, July 30 by Jefferies.
More recent Puretech Health PLC (LON:PRTC) news were published by: Businesswire.com which released: “PureTech Health to Present at the Jefferies 2016 Healthcare Conference in London” on November 02, 2016. Also Fiercebiotech.com published the news titled: “PureTech Health plc Successfully raises $171 million (£108 million) in Premium …” on June 19, 2015. Bostonglobe.com‘s news article titled: “PureTech’s long view on biopharma” with publication date: August 27, 2015 was also an interesting one.
PureTech Health plc is a cross-disciplinary healthcare company. The company has a market cap of 316.76 million GBP. The Firm operates through two divisions: growth stage businesses and project phase businesses. It currently has negative earnings. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.